| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/31/2023 | 412.38% | HC Wainwright & Co. | → $3 | Reiterates | → Buy |
| 08/13/2020 | 497.78% | Aegis Capital | $3.25 → $3.5 | Maintains | Buy |
| 01/27/2020 | 412.38% | Piper Sandler | → $3 | Initiates Coverage On | → Overweight |
| 01/24/2020 | 412.38% | SunTrust Robinson Humphrey | → $3 | Initiates Coverage On | → Buy |
| 06/26/2019 | 583.18% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
| 05/17/2019 | 753.97% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 02/11/2019 | — | Roth Capital | Initiates Coverage On | → Buy | |
| 11/13/2018 | 753.97% | Maxim Group | $2 → $5 | Maintains | Buy |
| 08/13/2018 | 241.59% | Maxim Group | $3 → $2 | Maintains | Buy |
| 07/10/2018 | 412.38% | Maxim Group | $4 → $3 | Maintains | Buy |
What is the target price for Matinas BioPharma Hldgs (MTNB)?
The latest price target for Matinas BioPharma Hldgs (AMEX: MTNB) was reported by HC Wainwright & Co. on January 31, 2023. The analyst firm set a price target for $3.00 expecting MTNB to rise to within 12 months (a possible 412.38% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Matinas BioPharma Hldgs (MTNB)?
The latest analyst rating for Matinas BioPharma Hldgs (AMEX: MTNB) was provided by HC Wainwright & Co., and Matinas BioPharma Hldgs reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Matinas BioPharma Hldgs (MTNB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Matinas BioPharma Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Matinas BioPharma Hldgs was filed on January 31, 2023 so you should expect the next rating to be made available sometime around January 31, 2024.
Is the Analyst Rating Matinas BioPharma Hldgs (MTNB) correct?
While ratings are subjective and will change, the latest Matinas BioPharma Hldgs (MTNB) rating was a reiterated with a price target of $0.00 to $3.00. The current price Matinas BioPharma Hldgs (MTNB) is trading at is $0.59, which is within the analyst's predicted range.